Recently, CXCR3 has also gained considerable attention in enhancing ACT.60 This interest stems from the observation that PD-1 blockade and/or chemotherapy has been shown to promote ACT recruitment in a CXCR3-ligand-dependent manner.61,62 A growing body of evidence corroborates the observation that the chemokine landscape within a given tumour can be extremely heterogenous,63 illustrating the need to identify specific candidates and strategies to enhance T cell infiltration into different cancers, which will vary from patient to patient. The gene discussed is PDCD1; the disease is neoplasm.